BioWorld

March 2, 2005

Diabetes Drug Glumetza Gets Approvable Letter From FDA

The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today) Read More

Tysabri Crisis Causes Analysts To Downgrade, Revise Models

Perlegen Building Pipeline Via $74M Financing Round

Follow-On Protein Meeting Sheds More Light On Topic

Discovery Acquires Biofrontera, Expects To Lose Money In 2005

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...